Jiřı́ Schwarz

936 total citations
36 papers, 403 citations indexed

About

Jiřı́ Schwarz is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Jiřı́ Schwarz has authored 36 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 21 papers in Hematology and 19 papers in Molecular Biology. Recurrent topics in Jiřı́ Schwarz's work include Acute Myeloid Leukemia Research (19 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Jiřı́ Schwarz is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Jiřı́ Schwarz collaborates with scholars based in Czechia, Germany and France. Jiřı́ Schwarz's co-authors include K Michalová, Jana Marková, Jana Březinová, Petr Cetkovský, Ota Fuchs, C Haškovec, Jacqueline Maaloufová, Hendrik De Raeve, Melanie J. Percy and King H. Lam and has published in prestigious journals such as Blood, Journal of Hematology & Oncology and European Journal of Human Genetics.

In The Last Decade

Jiřı́ Schwarz

35 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiřı́ Schwarz Czechia 11 249 245 220 64 47 36 403
Heather Cazzolli United States 5 204 0.8× 270 1.1× 157 0.7× 33 0.5× 41 0.9× 8 369
Mayuka Nakatake Japan 9 226 0.9× 238 1.0× 246 1.1× 71 1.1× 49 1.0× 14 431
Julia Romani Germany 9 102 0.4× 150 0.6× 181 0.8× 28 0.4× 32 0.7× 11 333
Yoshitaka Sunami Japan 10 307 1.2× 263 1.1× 246 1.1× 70 1.1× 41 0.9× 18 449
Ilaria S. Pagani Australia 9 161 0.6× 195 0.8× 87 0.4× 74 1.2× 18 0.4× 21 318
T. Haferlach Germany 7 118 0.5× 197 0.8× 142 0.6× 24 0.4× 33 0.7× 10 283
G. A. Wilson United Kingdom 3 247 1.0× 513 2.1× 214 1.0× 25 0.4× 46 1.0× 4 566
Kaddour Chabane France 10 126 0.5× 128 0.5× 86 0.4× 52 0.8× 22 0.5× 17 242
Fiona Watkins United Kingdom 6 117 0.5× 246 1.0× 180 0.8× 18 0.3× 28 0.6× 8 379
Yin Wei Ho United States 3 127 0.5× 291 1.2× 127 0.6× 37 0.6× 86 1.8× 8 369

Countries citing papers authored by Jiřı́ Schwarz

Since Specialization
Citations

This map shows the geographic impact of Jiřı́ Schwarz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiřı́ Schwarz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiřı́ Schwarz more than expected).

Fields of papers citing papers by Jiřı́ Schwarz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiřı́ Schwarz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiřı́ Schwarz. The network helps show where Jiřı́ Schwarz may publish in the future.

Co-authorship network of co-authors of Jiřı́ Schwarz

This figure shows the co-authorship network connecting the top 25 collaborators of Jiřı́ Schwarz. A scholar is included among the top collaborators of Jiřı́ Schwarz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiřı́ Schwarz. Jiřı́ Schwarz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marková, Jana, et al.. (2023). A novel germline hyperactivating JAK2 mutation L604F. Annals of Hematology. 102(10). 2725–2734.
2.
Košťál, Milan, et al.. (2020). Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide. Journal of Thrombosis and Thrombolysis. 51(1). 112–119. 8 indexed citations
3.
Vydra, Jan, Cyril Šálek, Jiřı́ Schwarz, et al.. (2017). Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission. Clinical Lymphoma Myeloma & Leukemia. 18(2). 106–113. 2 indexed citations
4.
Hussein, Kais, Melanie J. Percy, Mary Frances McMullin, et al.. (2013). Clinical utility gene card for: Hereditary thrombocythemia. European Journal of Human Genetics. 22(2). 293–293. 7 indexed citations
5.
Marková, Jana, C Haškovec, Ota Fuchs, et al.. (2012). Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation. Leukemia Research. 36(9). 1128–1133. 40 indexed citations
6.
Poläk, Jaroslav, et al.. (2012). Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs. Blood Cells Molecules and Diseases. 49(1). 41–47. 11 indexed citations
7.
Marková, Jana, Jana Březinová, K Michalová, et al.. (2011). Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. European Journal Of Haematology. 88(2). 128–135. 58 indexed citations
8.
Marková, Jana, et al.. (2011). Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression. Experimental and Therapeutic Medicine. 3(1). 129–133. 10 indexed citations
9.
Lemež, P, Hana Klamová, Zuzana Zemanová, et al.. (2011). Unusually Long Survival of a 67-Year-Old Patient with Near-Tetraploid Acute Myeloid Leukemia M0 without Erythroblastic and Megakaryocytic Dysplasia. Acta Haematologica. 126(3). 129–134. 7 indexed citations
10.
Schwarz, Jiřı́, Miroslav Penka, Petra Ovesná, et al.. (2011). Thrombosis in MPN with Thrombocythemia Is Associated with Higher Platelet Count At the Time of the Event: Data From the Czech Registry of Patients Treated with Anagrelide,. Blood. 118(21). 3857–3857. 1 indexed citations
11.
Doubek, Michael, Jiřı́ Mayer, Petra Obrtlíková, et al.. (2011). Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. European Journal Of Haematology. 87(2). 130–137. 13 indexed citations
12.
Peková, Šoňa, Robert Ivánek, Michal Dvořák, et al.. (2009). Molecular variability of FLT3/ITD mutants and their impact on the differentiation program of 32D cells: Implications for the biological properties of AML blasts. Leukemia Research. 33(10). 1409–1416. 4 indexed citations
13.
Fuchs, Ota, Jana Březinová, Roman Kotlín, et al.. (2009). Nature of frequent deletions in CEBPA. Blood Cells Molecules and Diseases. 43(3). 260–263. 1 indexed citations
14.
Fuchs, Ota, R Neuwírtová, Petr Kobylka, et al.. (2008). CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Molecules and Diseases. 40(3). 401–405. 36 indexed citations
15.
Michiels, Jan, Hendrik De Raeve, Konnie M. Hebeda, et al.. (2007). WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leukemia Research. 31(8). 1031–1038. 33 indexed citations
16.
Zenz, Thorsten, Martin Trbušek, Jana Šmardová, et al.. (2007). p53 Inactivation in CLL: Pattern of 110 TP53 Mutations.. Blood. 110(11). 2064–2064. 2 indexed citations
17.
Schwarz, Jiřı́, Robert Pytlík, Michael Doubek, et al.. (2006). Analysis of Risk Factors: The Rationale of the Guidelines of the Czech Hematological Society for Diagnosis and Treatment of Chronic Myeloproliferative Disorders with Thrombocythemia. Seminars in Thrombosis and Hemostasis. 32(3). 231–245. 6 indexed citations
18.
Michalová, K, Zuzana Zemanová, Jana Březinová, et al.. (2005). Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics. 160(1). 27–34. 31 indexed citations
19.
Schwarz, Jiřı́, Adam Jirásek, Marek Trněný, et al.. (2001). Aleukemic granulocytic sarcoma with AML1/ETO fusion gene expression and clonal T cell populations. Leukemia Research. 25(12). 1137–1142. 3 indexed citations
20.
Schwarz, Jiřı́, et al.. (1987). Features of immaturity in cells derived from granulocytic differentiation inducer treated human myeloid leukaemia (ML-1) cells. Leukemia Research. 11(10). 869–876. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heather Cazzolli Breakdown of academic impact, for papers by Mayuka Nakatake Breakdown of academic impact, for papers by Julia Romani Breakdown of academic impact, for papers by Yoshitaka Sunami Breakdown of academic impact, for papers by Ilaria S. Pagani Breakdown of academic impact, for papers by T. Haferlach Breakdown of academic impact, for papers by G. A. Wilson Breakdown of academic impact, for papers by Kaddour Chabane Breakdown of academic impact, for papers by Fiona Watkins Breakdown of academic impact, for papers by Yin Wei Ho
Rankless by CCL
2026